Harbor — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Developing next-generation immunotherapies for oncology and inflammatory diseases.

OncologyImmunologyInfectious Disease

A proprietary platform for engineering targeted immunomodulators, including bispecific antibodies and tuned cytokines.

Significant market potential exists for effective, safer immunotherapies in hard-to-treat cancers and autoimmune diseases.

Clinical failure of their lead candidate would severely impact valuation and funding prospects.

Faces intense competition from large pharma and numerous biotechs in immuno-oncology, requiring clear differentiation.